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Purpose: Safety and efficiency are critical for successful gene therapy. Adeno-associated viral (AAV) vectors are
commonly used for gene transfer in both human and animal studies. However, administration of AAV vectors can lead
to development of neutralizing antibodies against the vector capsid, thus decreasing the efficiency of therapeutic gene
transfer and preventing effective vector readministration. We investigated immune responses to different routes of ocular
administration and readministration of AAV vectors, and the effect of previous exposure of AAV vector in one eye on
the transduction efficacy of subsequent intraocular AAV-mediated gene delivery to the partner eye.
Methods: We tested two vector systems. One contained a cDNA encoding a secreted pigment epithelial derived factor
(PEDF) cDNA under the control of a Cytomegalovirus (CMV) enhancer and chicken β-actin promoter (CBA; AAV2-
CBA-PEDF) and was tested in a murine model of laser-induced choroidal neovascularization (CNV). The other vector
contained a cDNA encoding the intracellular reporter green fluorescent protein (GFP) under the control of the same
promoter  (AAV2-CBA-GFP).  Animals  were  divided  into  groups  and  received  sequential  injections  at  different
combinations of either intravitreal or subretinal routes. CNV was evaluated by fluorescein angiographic choroidal flat-
mount image analysis. The expression of GFP was analyzed in retinal sections by direct fluorescence imaging. Antibodies
against AAV2 capsid and transgenes were analyzed by ELISA using serum samples collected before injection and different
time points after the injection. Neutralizing antibodies were characterized by in vitro assays.
Results: Various ocular compartments responded to AAV administration differently. Intravitreal administration of AAV
vectors, which resulted in transduction of inner retina (primarily retinal ganglion cells), generated a humoral immune
response against AAV capsid that blocked vector expression upon readministration via the same route into the partner
eye. In contrast, it had no effect on vector readministered into the subretinal space of the partner eye. Additionally,
subretinal administration of vector did not trigger any humoral immune response against AAV capsid, and had no effect
on subsequent administration of vector either intravitreally or subretinally into the partner eye.
Conclusions: These findings have important clinical implications for the design of AAV-mediated ocular gene transfer
for retinal diseases, particularly if both eyes require sequential treatment.
Despite  the  many  advantageous  properties  of  adeno-
associated  viral  (AAV)  vectors  to  deliver  potentially
therapeutic genes to the tissue of choice, preexisting immunity
due to prior exposure with wild-type (wt) AAV vectors in the
majority of the human population could potentially limit their
therapeutic  usefulness  [1-6].  In  animal  studies,
preimmunization with recombinant AAV vectors has resulted
in  reduction  or  lack  of  transgene  expression  [3,7,8]  and
correlated with the presence of neutralizing antibody (nAB)
found  in  the  serum.  Moreover,  studies  of  repeated
administration  of  AAV  vectors  indicate  that  immune
responses  generated  after  an  initial  administration  may
prevent  or  mute  further  vector-mediated  cell  transduction
[9-14]. The presence of high levels of nAB against wt AAV
also reduced AAV-mediated gene transfer in the brain [4].
Several strategies have been developed to circumvent these
responses (reviewed in [15]).
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The eye is considered to be an immunologically protected
space (reviewed in [16]). The origin of this immune privilege
is  complex  and  is  generated  by  multiple  layers  and
mechanisms  including  the  blood-retina  barrier  and  other
physical barriers, an immunosuppressive microenvironment,
and the existence of deviant systemic immunity that limits the
production of proinflammatory effector cells (reviewed in
[17]). These mechanisms provide the eye with a degree of
immune protection that lacks acute, destructive inflammation,
thus sparing the delicate visual axis which is incapable of
regeneration after early development. It is commonly assumed
that preexposure to AAV may not pose significant problems
with regard to the performance of AAV vectors in the eye
because of this ocular immune privilege. Few studies have
focused on the impact of previous systemic immune response
to AAV on transduction efficacy of AAV vectors in distinct
ocular spaces, such as the intravitreal cavity and subretinal
space.  In  addition,  how  the  immune  system  responds  to
administration and readministration of AAV vectors in these
ocular compartments is poorly understood.
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1760In  this  study,  we  investigated  immune  responses  to
different routes of ocular administration and readministration
of AAV vectors, and the effect of previous exposure of AAV
vector in one eye on the transduction efficacy of subsequent
intraocular AAV-mediated gene delivery to the partner eye.
We tested two vector systems. One contains a cDNA encoding
a secreted pigment epithelial derived factor (PEDF) under the
control of a CMV enhancer and chicken β-actin promoter
(CBA; AAV2-CBA-PEDF) which has been previously shown
to inhibit the choroidal neovascularization (CNV) in a murine
model [18]. The other vector contains a cDNA encoding the
intracellular reporter green fluorescent protein (GFP) under
the control of the same promoter (AAV2-CBA-GFP). We
show that, although the eye is an immune-privileged site,
various ocular compartments respond to vector administration
differently. Intravitreal administration of AAV vectors, which
results  in  transduction  of  inner  retinal  cells,  generated  a
humoral immune response against AAV capsid that blocked
expression  from  readministered  intravitreal  vector  in  the
partner eye. However, intravitreal vector in the first eye had
no effect on readministering vector into the subretinal space
of the partner eye where photoreceptor and retinal pigment
epithelial  (RPE)  cells  were  transduced.  Moreover,  if  the
initially treated eye received subretinal vector, no humoral
immune response against AAV capsid was elicited, and no
effect on subsequent administration of the AAV vector either
intravitreally  or  subretinally  ensued.  Although  both
intramuscular and intravitreous injections elicited production
of neutralizing antibody against AAV2 capsid, the profile of
immunoglobulin classes was different, reflecting the ocular
regulatory immune modulation of the immune response.
METHODS
AAV serotype 2 production and purification: A fused CBA
was used to drive expression of GFP and human PEDF in
recombinant  AAV2,  based  on  pTR-UF  vectors  [19].  The
construction and production of CBA-PEDF-AAV2 has been
described  previously  in  which  the  human  PEDF  gene  is
expressed  from  the  CBA  promoter  [18].  Vectors  were
produced  and  purified  as  previously  described  [20,21].
Briefly,  HEK  293  cells  were  cotransfected  with  the
appropriate pTR-UF and the helper plasmid pDG DNAs for
48–60 h. Cells were harvested, and the crude lysate purified
through  an  iodixanol  step  gradient  followed  by  Mono-Q
FPLC  chromatography.  The  vector  genome  (vg)  titers  of
AAV2 particles were determined by real-time PCR.
Animals,  injections,  and  tissue  process:  All  mouse
experimentation  was  performed  under  approved  protocols
from  the  University  of  Florida  Animal  Care  and  Use
Committee  and  in  accordance  with  National  Institutes  of
Health guidelines. Wild-type C57BL/6J mice (6-8 weeks of
age) were obtained from The Jackson Laboratory (Bar Harbor,
ME).  For  intramuscular  (IM)  injections,  approximately
4x1010 vector genome (vg) per animal was delivered (n=5).
For  ocular  injections,  1  μl  of  AAV2-CBA-PEDF  vector
(approximately 4x109 vg) was injected intravitreally (15 mice
per  treatment  group)  or  1  μl  of  AAV2-CBA-GFP  vector
(approximately 2x109 vg) was injected either intravitreally or
subretinally (5 animals per group). Detailed techniques for
intravitreal  and  subretinal  injections  have  been  described
previously [18,22]. For GFP expression analysis, mice were
sacrificed  at  the  end  of  the  experiments.  The  mice  were
sacrificed  by  ketamine  (150  mg/kg)/xylazine  (10  mg/kg)
overdose  followed  by  cervical  dislocalization.  Their  eyes
were enucleated, fixed in 4% paraformaldehyde for 2–4 h at
room temperature, cryoprotected in 30% sucrose, embedded
in optimal cutting temperature (OCT) embedding medium,
and quickly frozen. Transverse sections of the eye were cut at
12  μm,  mounted  on  slides,  and  GFP  fluorescence  was
examined under a Zeiss microscope (Axiovert 200, Carl Zeiss
MicroImaging,  Inc.,  Thornwood,  NY)  equipped  with
epifluorescence  illumination  and  a  digital  camera
(AxionCamMR, Carl Zeiss MicroImaging, Inc., Thornwood,
NY).
Laser-induced CNV mouse model: The mouse CNV model
was induced as previously described [18]. Briefly, adult mice
were anesthetized, and eyes dilated. A 532 nm diode laser
(Oculight SLx; Iridex Co., Mountain View, CA) was used
with a 100 μm spot size at 0.1 s exposure and 300 mW power.
Laser photocoagulation was delivered through a slit lamp with
a cover slide employed as a contact lens. A pattern of 4–6
lesions  was  placed  concentrically  around  the  optic  nerve.
Formation  of  a  bubble  indicated  rupture  of  Bruch’s
membrane.  To  quantitatively  evaluate  CNV  two  weeks
following laser treatment, we prepared flatmounts of sclera,
choroid, and RPE that we imaged using a Zeiss fluorescence
microscope  (AxioVision,  Carl  Zeiss  MicroImaging,  Inc.,
NY). The neovascular area at each laser lesion was measured
with a Zeiss AxioVision Software measurement tool, and the
data was expressed in μm2.
Enzyme-linked  immunosorbent  assays:  To  detect  serum
antibodies  to  AAV2  capsid,  we  coated  enhanced  protein-
binding  ELISA  plates  with  109  vg/ml  of  AAV2  at  4  °C
overnight. The plates were blocked at 37 °C for 2 h then
incubated at 4 °C overnight with serially diluted anti-AAV2
monoclonal antibody (Industries International, Concord, MA)
or 1:50, 1:100, 1:200, or 1:400 dilutions of mouse sera. Next,
the plates were incubated with HRP-conjugated anti-mouse
Ig at 37 °C for 2 h, then with TMP substrate and H2O2. The
reaction was stopped by H3PO4 and read at 450 nm on an
EL808 plate reader. The titer of anti-AAV2 antibodies was
calculated based on the standard curve of the commercial
antibody determined in parallel. Each value was determined
in triplicate.
To detect antibodies against transgenes (GFP and PEDF),
we coated the microplates with either 5 μg/ml purified GFP
(generously provided by Clay Smith, University of Florida),
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Middletown, MD), followed by incubation with mouse sera
as described in the previous section. Commercial monoclonal
antibodies  to  GFP  (Invitrogen,  Carlsbad,  CA)  and  PEDF
(Santa Cruz Biotechnology Inc., Santa Cruz, CA) were used
as positive controls. Isotyping of the antibody responses was
performed using a commercial kit (Southern Biotechnology,
Birmingham,  AL)  according  to  the  manufacturer’s
instruction.
Neutralizing  antibody  assay:  To  detect  neutralizing
antibodies to AAV2, we incubated 1:20, 1:60, 1:180, 1:540,
1:1620, or 1:4860 mouse serum samples with 108 vg AAV2-
GFP in 25 µl of PBS for 2 h at 4 °C. This mix was added to
each well of HEK 293 cells grown in a 24 well plates (to
achieve a multiple of infection (MOI) at 1000). The cells were
grown at 37 °C in 5% CO2, in Dulbecco's Modified Eagle's
Medium (DMEM; HyClone, Logan, UT) containing 5% FBS
(HyClone). Each sample was run three times. GFP expression
was evaluated 48 h after infection by cell counting. Percentage
of inhibition was calculated with no-antibody control samples
as a reference.
Statistics: All values are expressed as means±SD. Statistical
analysis was performed with unpaired, two-tailed Student t-
tests for single comparisons. A p-value of < 0.05 was taken to
indicate a significant difference.
RESULTS
Intravitreal  injection  of  CBA-PEDF-AAV2  results  in  a
humoral immune response against AAV2 capsid and prevents
therapy upon vector re-administration in the contralateral
eye: In an initial attempt to emulate clinical situations where
contralateral eyes are treated sequentially with therapeutic
genes delivered via AAV vectors, we tested the CBA-PEDF-
AAV2 vector in a laser-induced mouse CNV model. We chose
this construct and animal model because previous results have
shown that it efficiently inhibited neovascularization in laser-
induced CNV mouse model [18].
Wild-type  C57BL/6J  mice  were  divided  into  three
groups. Group 1 received a single intravitreal injection of
CBA-PEDF-AAV2 vector in right eye only. Group 2 received
an intravitreal injection of the vector into the right eye; two
months later, they were given a second intravitreal injection
of the vector in the left eye. Group 3 received an IM injection
of  the  vector  first  to  preimmunize  systemically  with  the
vector. They were then given an intravitreal injection of vector
into the right eye. Both eyes from all groups were then lasered
to induce CNV two months after the second injection or at an
equivalent time for Group 1. All mice were sacrificed two
weeks after laser treatment to quantitatively evaluate the level
of CNV development.
There was a significant reduction of CNV (Figure 1B,E),
as reported previously [18], in eyes from mice that received a
single intravitreal injection of AAV2-CBA-PEDF (Group 1).
Right eyes that received intravitreal injection of the vector
followed by an intravitreal vector injection into their left eyes
(Group 2) showed a similar level of CNV reduction as mice
receiving a single treatment (Figure 1C,E). However a second
vector administered intravitreally to contralateral eyes had no
effect on CNV development (Figure 1D,E). Vector-treated
eyes from mice previously exposed to AAV vector through
IM  injection  also  showed  no  therapeutic  difference  from
untreated eyes (Figure 1E). Thus it appeared that the mouse’s
immune status with regard to AAV vector may define whether
or  not  intravitreal  vector  could  effectively  express  a
therapeutic gene.
To test this idea, the anti-AAV capsid immune status of
these animals was determined from serum samples collected
before the first injection, at one month, and two months after
the  first  injection  (before  second  injection),  then  at  four
months after the first injection. The presence of anti-AAV2
capsid  antibodies  in  the  serum  samples  was  analyzed  by
ELISA. Serum antibody against AAV2 capsid was found in
all  animals  receiving  intravitreal  injections  at  a  level
equivalent to that seen in animals receiving IM administration,
Group 3 (Figure 1F). No CNV therapy was evident in Group
3 animals previously immunized with IM vector. Therefore
the presence of circulating capsid antibody correlated with the
failure  of  intravitreal  AAV2-CBA-PEDF  vector  to  inhibit
CNV.
The  route  of  intraocular  vector  delivery  defines  systemic
immune responses against AAV2 capsid and affects transgene
expression from readministered vector in the partner eye: The
inability  of  vector-treated  second  eyes  to  respond  to  the
antineovascular  effects  of  AAV2-CBA-PEDF  after  laser
treatment prompted us to examine in more detail both the
immune status and therapeutic potential of ocular vector as a
function of its intraocular site of delivery. Ocular tissues,
particularly  the  anterior  chamber,  vitreal  cavity,  and
subretinal space, are immune privileged sites (reviewed in
[16]). It is generally assumed that neutralizing antibodies in
the  circulation  cannot  penetrate  the  blood-ocular-barriers;
thus  previous  exposure  to  AAV,  which  may  diminish  or
completely prevent systemic administration of AAV vectors,
should have minimal effect on AAV-mediated gene transfer
in ocular tissues. The aforementioned view of the eye and the
immune system prompted us to systematically investigate
how the immune system responds to AAV-mediated gene
transfer  into  different  intraocular  compartments  and  the
impact of such responses upon readministering vector to the
contralateral eye of the same animal.
For these experiments, we used a GFP reporter gene
(under the control of the same CBA promoter in the same
AAV2  vector  backbone  as  described),  so  that  vector
transduction of different retinal cell types could be easily
visualized  in  tissue  sections.  Wild-type  C57  mice  were
divided  into  four  groups  and  subjected  to  different
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1762combinations of sequential ocular injections. Mice received
either an intravitreal (IV) or subretinal (SR) injection into one
eye, then a second invitreal or subretinal injection two months
after the first. All mice were sacrificed one month after second
injection (three months after the first injection). Group 1 mice
received vector intravitreally followed by intravitreal vector
in  the  partner  eye  two  month  after  the  first  vector
administration,  Group  2  received  vector  intravitreally
followed by subretinal vector in the partner eye, Group 3
received vector subretinally followed by intravitreal vector in
the partner eye, and Group 4 received vector subretinally
followed by subretinal vector in the partner eye. Retinas were
then  analyzed  in  transverse  tissue  sections  for  GFP
expression.  Blood  samples  were  collected  before  vector
Figure 1. Therapeutic effect of CBA-
PEDF-AAV2  on  choroidal
neovascularization  development  and
antibody  responses  to  AAV2  capsid
following  single  and  sequential
intravitreal  injections.  A-D:
Representative  CNV  images  from
mouse  eyes  that  were  untreated  (A),
received  a  single  intravitreal  (IV)
treatment  (B),  received  first  IV
treatment (C), and received a second IV
treatment (D) of AAV2-PEDF. E: The
therapeutic  effect  of  CBA-PEDF-
AAV2  on  CNV  development  was
evaluated in animals that received single
IV  ocular  injections  in  naïve  and
preimmunized  mice  (5  animals  each
type of injection), and two sequential IV
injections (15 animals were used). The
CNV area was averaged from 25 laser
lesions  (from  5  mice)  for  mice  that
received a single IV injection and pre-
intramuscular  (pre-IM)  administration
of the vector, and 75 laser lesions (from
15  mice)  for  mice  that  received  two
sequential  intravitreal  injections  (2X-
IV).  F:  Antibody  response  to  AAV2
capsid  in  animals  received  a  single
intramuscular injection, intravitreal, and
two  sequential  intravitreal  injections
overtime.  Five  animals  for  each  type
vector  injection  were  used.  Arrow
indicates the second injection time.
TABLE 1. SUMMARY OF RETINAL GFP EXPRESSION IN ANIMALS RECEIVING DIFFERENT COMBINATIONS OF SEQUENTIAL
INTRAOCULAR INJECTIONS OF AAV2-CBA-GFP VECTOR
Group
First injection Second injection
GFP expression Cell types GFP expression             Cell types
Group 1 (IV-IV) +++ mainly RGC none n/a
Group 2 (IV-SR) +++ mainly RGC +++ PR and RPE
Group 3 (SR-IV) +++ PR and RPE +++ mainly RGC
Group 4 (SR-SR) +++ PR and RPE +++ PR and RPE
Group 1 animals received two sequential intravitreal (IV) injections of the vector. Group 2 animals received IV injection in the
first eye, followed by SR injection in the second eye. Group 3 received SR injection in first eye, followed by IV injection in the
second eye. Group 4 animals received two sequential subretinal (SR) injections. Abbreviations: intravitreal (IV); subretinal
(SR); retinal ganglion cells (RGC); photoreceptors (PR); retinal pigment epithelial cells (RPE), green fluorescent protein (GFP).
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1763injection, and then at one month, two months (just before the
second injection), and finally at three months after the first
injection. These samples were analyzed for the presence of
antibody  against  AAV2  capsid.  We  chose  to  perform  the
second injection at two months after the first, because in
previous experiments an intravitreal delivered vector elicited
serum anti-AAV antibody levels that peaked at approximately
this time (Figure 1F).
Results of these experiments are summarized in Table 1.
Images of GFP expression in representative retinas from both
eyes in each group of animals are shown in Figure 2. In Group
1  the  initial  intravitreal  injection  of  CBA-GFP-AAV2
efficiently  transduced  mainly  retinal  ganglion  cells  as
expected (Figure 2A,B,E,F). In contrast, a second intravitreal
injection two months later into the partner eye yielded no
transduction of any retinal cells (Figure 2C,D). Yet when the
second vector injection into the partner eye was delivered to
the  subretinal  space  (Group  2),  there  was  the  expected
efficient  GFP  transgene  expression  in  photoreceptors  and
RPE cells (Figure 2G,H). Conversely, an initial subretinal
vector prevented neither subsequent intravitreal (Group 3,
Figure 2I,J,K,L) or subsequent subretinal (Group 4, Figure
2M,N,O,P)  vector  from  transducing  target  retinal  cells
normally.
The absence of GFP expression in the second eyes of
Group  1  mice  after  an  initial  intravitreal  vector  exposure
correlated with the presence of antibody against AAV2 after
this first vector (Figure 3). This was also seen in the initial
Figure 2. GFP expression in retinas receiving different routes of intraocular vector sequentially in partner eyes. Representative images of
retinas from each treatment group listed in Table 1 are shown in the same order. A, B, E, F, I, J, M, and N show retinas that received first
eye vector injections. C, D, G, H, K, L, O, and P present retinas that received second eye vector injections. A-D show retinas that received
two sequential intravitreal injections (IV-IV) vector injections. E-H are from retinas that were given two sequential injections with first eye
injected intravitreally and second subretinally (IV-SR) vector injections. I-L present retinas that received two sequential injections with first
eye injected subretinally and second intravitreally (SR-IV) vector injections. M-P represent retinas that received two sequential subretinal
injections (SR-SR) vector injections. A low-magnification image from each eye is shown on the right for each treatment group with a higher
magnification image from the same eye next to it on the right (e.g., image B is taken from A, image D is taken from C, and so forth).
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1764experiment  with  intravitreal  CBA-PEDF-AAV2  described
(Figure 1E). The presence of serum anti-AAV2 antibody in
Group 2, which received an intravitreal injection first and then
a  subretinal  injection  of  the  vector,  did  not  prevent
photoreceptor and RPE cell transduction by the second vector
(Figure 2G,H). Mice that received subretinal injections first
did not generate significant levels of anti-AAV2 antibody
(Figure 3); such vector had no effect on GFP expression from
subsequently readministered vector into the partner eye, either
intravitreally or subretinally (Figure 2I-P, and Table 1).
Identification of neutralizing antibodies to AAV2 capsid: To
determine the neutralizing capability of antibodies against
AAV2 capsid from mice who received different injections of
AAV2 (IV, SR, and IM), we incubated serum samples with
threefold serial dilutions with CBA-GFP-AAV2 vector (MOI
1000) for 2 h at 4 °C before infecting HEK293 cells. As shown
in Figure 4, serum samples from mice that received IV and
IM injection of AAV2 (four weeks postinjection) contained
neutralizing antibodies to AAV2 capsid, whereas serum from
mice received SR injection did not show significant level of
nAb to AAV2 capsid.
We  also  tested  humoral  responses  to  transgenes  by
ELISA. No antibodies against either the cytoplasmic protein
GFP, or the secreted protein PEDF were detected in mouse
sera received either intramuscular or intravitreal injections
(data not shown).
To  compare  the  immunoglobulin  profile,  we  also
performed isotyping using commercial kit. Although mouse
sera from both IM and IV injections contained neutralizing
antibodies against AAV2 capsid (Figure 3 and Figure 4), the
Figure 3. Serum antibody responses to AAV capsid in animals after
different sets of sequential intraocular AAV2-CBA-GFP injection.
Five animals for each group were used. Group 1 animals received
two sequential intravitreal (IV) injections of the vector. Group 2
animals received two sequential subretinal (SR) injections. Group 3
received SR injection in first eye, followed by IV injection in the
second eye. Group 4 animals received IV injection in the first eye,
followed by SR injection in the second eye.
IgG subclasses are very different: sera from mice that received
IM injections contained high level of IgG2a, but scant or no
detectable  levels  of  IgG2b,  whereas  sera  from  mice  that
received  IV  injections  contained  mostly  IgG2b  and  no
detectable IgG2a.
DISCUSSION
AAV  vectors  have  many  attractive  features  for  safe  and
efficient gene therapy, including their lack of pathogenesis,
low toxicity, ability to efficiently infect both dividing and
nondividing cells in a broad range of host tissues or organs,
and long-term gene expression [23,24]. The eye, considered
an extension of the CNS, has many unique advantages as a
target for gene therapy to treat both inherited and acquired
ocular diseases. The ability of AAV vectors to efficiently
transduce  target  retinal  cell  types  has  been  exploited  to
successfully transfer therapeutic genes into photoreceptors,
retinal pigment epithelium, and the inner retina to treat a
variety of retinal diseases causing blindness [25-29] [22,30,
31].
An estimated 80% of the population maintain antibodies
to  the  capsid  proteins  of  wt  AAV2,  and  30%–84%
demonstrate the presence of nAb [2,32-37]. Since natural
Figure 4. Neutralizing antibodies to AAV2 capid using in vitro assay.
Serum samples were collected from animals at four weeks after
receiving  different  route  of  injections  (IM:  intramuscular;  IV:
intravitreal; SR: subretinal), as well as from naïve animals that have
not  been  exposed  to  AAV  vector  previously.  Each  sample  was
serially  diluted.  Each  serum  sample  from  serial  dilutions  was
incubated with AAV GFP virus before infecting HEK293 cells. The
percentage of inhibition was calculated using no-serum AAV2-GFP
as  the  reference.  Abbreviations:  intramuscular  injection  (IM);
intravitreal injection (IV); subretinal injection (SR). Serum samples
from 4 animals were used for each route of injection of the AAV
vector.
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1765exposure to wt AAV is quite common in human population,
this poses a possible threat to the efficacy as well as the safety
of AAV vector administration [1-6]. Moreover, studies of
repeated administration of AAV vectors into nonocular tissue
indicate  that  immune  responses  generated  after  the  first
administration may prevent further application [9-14]. It is
generally assumed that previous exposure to AAV will not
pose significant problems for the efficacy of AAV vectors in
the retina, an immune-privileged site. This notion is supported
by the observation that subretinal readministration of AAV
vectors resulted in additional transduction events despite the
presence  of  serum  antibodies  to  AAV  vectors  [38,39].
However, few studies have examined the impact of previous
systemic immune response to AAV capsid on transduction
and therapeutic efficacy of AAV vectors in different ocular
tissues, and little is known about how the immune system
responds to AAV vector administration and readministration
into different compartments of ocular tissues.
In the studies described in this report, we investigated
immune responses to different routes of ocular administering
and readministering AAV vectors, and the effect of previous
exposure  to  AAV  vector  on  the  therapeutic  efficacy  of
subsequent  intraocular  AAV-mediated  gene  delivery.  We
tested two vector systems, CBA-PEDF-AAV2 in a murine
laser induced CNV model, and CBA-GFP-AAV2, where the
ocular  tissue  transduction  can  be  directly  visualized.  We
showed that, although both vitreal cavity and subretinal space
are immune-privileged sites [40-47], when AAV vectors were
delivered  into  these  distinct  ocular  compartments,  they
triggered  immune  responses  differently.  Intravitreal
administration  of  AAV  vectors,  which  mostly  results  in
transduction of inner retina (mainly retinal ganglion cells),
generated humoral immune response against AAV capsid to
a  level  equivalent  to  systemic  (IM)  administration  of  the
vector.  The  presence  of  neutralizing  antibody  completely
blocked expression from readministered vector via the same
route, but had no effect on readministered vector if directed
into the subretinal space where photoreceptor and RPE cells
are  transduced.  Initial  subretinal  administration  of  AAV
vector did not trigger any humoral immune response against
AAV capsid and had no effect on subsequent intravitreal or
subretinal administration of vector.
Antigens introduced in the ocular microenvironment are
known to induce immune deviation. Such deviation has the
characteristics  of  antigen-specific  suppression  of  classical
Th1 immune responses such as delayed-type hypersensitivity
(DTH)  and  inability  of  producing  complement-fixing
antibodies, thus lacking classic inflammatory responses seen
in  other  nonimmune-privileged  tissues.  The  best
characterized ocular immune deviation is known as anterior
chamber-associated immune deviation (ACAID) [48-50]. It is
now  known  that  ACAID  is  a  complex  immunoregulatory
phenomenon that involves multiple organ systems and cell
populations. Such immune privilege has also been extended
to the vitreous cavity (VC) [41,45,46,51,52], and subretinal
(SR) space [41,43,44,47,53; also see recent review [54]. It is
intriguing  that  although  both  VC  and  SR  spaces  possess
immune privilege, the vitreal cavity behaved differently to
AAV-mediated  gene  transfer  in  inducing  the  systemic
immune response against AAV capsid in our experiment. The
underlying mechanism is unknown. However, it is possible
that the mechanism(s) contributing to the status of immune
privilege for the VC versus SR space is (or are) different. One
such  difference  may  be  due  to  VC  different  outflow
mechanisms, and anther may be due to its closer proximity to
vascular systems than the SR; both of these differences would
tend to offer VC more potential for presenting vector capsid
antigens to the immune system.
Anatomically, SR space and VC are situated in different
compartments of the posterior part of the eye and this may, in
part, explain the differences noted in immune response to
vector. The SR space is the virtual space between the RPE and
photoreceptors and is only present in retinal detachment. The
RPE monolayer forms the outer blood-retina-barrier (BRB),
separating the vessels of the choriocapillaris from the neural
retina,  and  controls  the  exchange  of  molecules  and  cells
between retina and choroid. RPE cells secrete a variety of
immune-suppressive  and  antiinflammatory  molecules  [55,
56]. These cells also express cell membrane-bound molecules,
such as FasL (CD95L), which induces apoptosis of CD95+
inflammatory cells and contribute to ocular immune privilege
[57,58]. More importantly, the SR space is thought to be
devoid  of  bone  marrow-derived  cells,  whereas  ACAID  is
induced  by  bone-marrow-derived  antigen  presenting  cells
(APC)  residing  in  the  anterior  chamber,  which  carry  an
antigen-specific signal via the circulation to the spleen [59].
In contrast, it is still not known how the signals that generate
immune deviation following antigen injection into SR space
escape the eye.
The vitreous cavity is the most posterior chamber of the
eye, situated between the lens and the retina, and is occupied
by the gelatinous vitreous body. Sonoda et al. [46] reported
that there was an antigen-specific immune deviation when
introduced  into  VC,  and  named  it  the  vitreous  cavity
associated  immune  deviation  (VCAID),  which  shares
common  mechanisms  with  ACAID.  Interestingly  these
authors found that bone marrow-derived “hyalocytes” in the
vitreous  are  actually  F4/80+,  and  may  serve  as  APCs
responsible for mediating this VCAID. Thus VCAID is more
similar to ACAID than the immune deviations induced by
antigens present in the SR space. This difference might also
contribute  to  the  difference  in  immune  response  to  AAV
vectors when delivered into these two different compartments
in  our  experiments.  Further  studies  are  needed  to  better
appreciate these mechanisms and advance our understanding
of  the  pathogenesis  of  many  other  ocular  diseases  of
immunological origin.
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of  Bennett  et  al.  [38]  and  Anand  et  al.  [39]  in  that  both
nonhuman primate and murine RPE and photoreceptor cells
can be transduced efficiently by AAV vectors in spite of the
presence of circulating antibodies to AAV capsid. However,
we  did  not  see  detectable  antibody  against  AAV  capsid
following  a  single  subretinal  injection  of  AAV  vector,
contrary  to  that  observed  by  Anand  et  al.  [39,60].  This
difference may result from different injection methods and
reagents used, or perhaps to escaped antigen at the injection
site following subretinal treatment where there is transient
disruption of outer BRB formed by RPE cells since it has been
shown that breakdown of RPE barrier function comprises the
status of ocular immune privilege [47].
In summary, the findings reported here have important
clinical  implications  in  designing  gene  therapy  protocols
aimed both at targeting different retinal cell types residing in
different ocular compartments and at treating partner eyes
sequentially. It may be possible to readminister AAV vectors
into the subretinal space to target photoreceptors as well as
the RPE without compromising the efficacy of repeated gene
transfers. However, for gene transfer targeting the inner retina
via  the  vitreous,  other  strategies  to  circumvent  immune
responses  may  be  required.  Such  strategies  include  using
different AAV serotypes (see recent review [61]), transient
immune suppression, and induction of immune tolerance (see
review in [15] and references therein). It should be pointed
out that these studies were performed in experimental animals
and cannot necessarily be directly extrapolated to humans
who comprise a far more immunologically heterogeneous
population than any animal research species. It should also be
pointed out that many factors contributing to the immune
privilege of subretinal space, such as the presence of blood-
retinal-barriers,  could  be  compromised  under  pathological
conditions  in  humans,  including  diabetic  retinopathy,  the
choriodal  neovascularization  seen  in  age-related  macular
degeneration, or ocular autoimmune diseases. Under such
conditions, immune responses to ocular AAV-mediated gene
transfer may also be different, and further studies are needed
to address these issues.
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